Related Experiment Video

Updated: May 23, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Anlotinib Plus Osimertinib in Osimertinib-Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A

Yu Hua1, Minghui Liu1, Boshi Li1

  • 1Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.

Thoracic Cancer
|May 21, 2025
PubMed
Abstract

Insights

Anlotinib plus osimertinib showed promising anti-tumor activity in non-squamous non-small cell lung cancer (NSCLC) patients progressing on osimertinib. This combination therapy demonstrated a manageable safety profile with significant disease control.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is a challenge in advanced EGFR-mutant non-small cell lung cancer (NSCLC).
  • Anlotinib combined with third-generation EGFR-TKIs has shown potential in overcoming acquired resistance.

Purpose of the Study:

  • To retrospectively evaluate the efficacy and safety of anlotinib plus osimertinib in patients with non-squamous NSCLC (nsq-NSCLC) who progressed after first-line osimertinib treatment.
  • To assess if this combination overcomes acquired resistance to prior EGFR-TKI therapy.

Main Methods:

  • Retrospective study of 28 nsq-NSCLC patients treated with anlotinib plus osimertinib after first-line osimertinib progression.
  • Outcomes assessed included progression-free survival (PFS1 for combination, PFS2 for prior osimertinib), objective response rate (ORR), disease control rate (DCR), and toxicity.

Main Results:

  • The median PFS with anlotinib plus osimertinib (PFS1) was 10.0 months.
  • The objective response rate (ORR) was 3.6%, and the disease control rate (DCR) was 85.7%.
  • All patients experienced toxicities, with 10.7% having grade 3 and no grade 4 events.

Conclusions:

  • Anlotinib plus osimertinib demonstrates encouraging anti-tumor activity in nsq-NSCLC patients with gradual progression on osimertinib.
  • The combination therapy presents a manageable safety profile, suggesting it as a viable option for this patient population.
Keywords:
anlotinibnonsquamous nonsmall cell lung cancerosimertinibresistance

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K